Related Experiment Videos
Summary
A young sickle cell disease patient developed multiple antibodies, including anti-Fy5, leading to a delayed hemolytic transfusion reaction after receiving Fy5 positive blood. Steroid therapy improved her autoimmune hemolytic anemia.
Area of Science:
- Hematology
- Immunology
- Transfusion Medicine
Background:
- Sickle cell disease (SCD) patients often develop alloantibodies due to chronic transfusion needs.
- Antibody development can complicate transfusion management and lead to hemolytic transfusion reactions.
- The Fy5 antigen system is a known target for alloimmunization in certain populations.
Observation:
- A 10-year-old African American female with SCD developed an anti-Fy5 antibody.
- Following transfusion with Fy5 positive blood, she experienced a delayed hemolytic transfusion reaction.
- Additional antibodies identified included anti-E, anti-C, and anti-K.
Findings:
- The patient presented with clinical features of autoimmune hemolytic anemia.
- A strongly positive direct antiglobulin test (DAT) and potent auto anti-I antibodies were detected.
- These findings indicate a complex immune response post-transfusion.
Implications:
- This case highlights the risk of alloimmunization and transfusion reactions in SCD patients, even with specific antibody development.
- Management of autoimmune hemolytic anemia in the context of alloantibodies requires careful consideration.
- Steroid therapy demonstrated efficacy in resolving the autoimmune hemolytic anemia in this patient.